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Semaphorin 4D (Sema4D; CD100) is a transmembrane homodimer 150-kDa glycopro-
tein member of the Semaphorin family. Semaphorins were first identified as chemorepel-
lants that guide neural axon growth. Sema4D also possesses immune regulatory activity. 
Recent data suggest other Sema4D functions: inactivation of platelets, stimulation of 
angiogenesis, and regulation of bone formation. Sema4D is a coupling factor expressed 
on osteoclasts that inhibits osteoblast differentiation. Blocking Sema4D may, therefore, 
be anabolic for bone. Sema4D and its receptor Plexin-B1 are commonly dysregulated 
in cancers, suggesting roles in cancer progression, invasion, tumor angiogenesis, and 
skeletal metastasis. This review focuses on Sema4D in bone and cancer biology and 
the molecular pathways involved, particularly Sema4D–Plexin-B1 signaling crosstalk 
between cancer cells and the bone marrow microenvironment—pertinent areas since a 
humanized Sema4D-neutralizing antibody is now in early phase clinical trials in cancers 
and neurological disorders.
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iNTRODUCTiON
Semaphorin 4D (Sema4D; also known as CD100), is a member of class IV of the Semaphorin protein 
family, with established functions as an immune regulator. This review focuses on additional, emerg-
ing roles of Sema4D in bone biology and cancer bone metastases. Recent pivotal findings support the 
pertinence of Sema4D in bone and cancers: (1) Negishi-Koga et al. (1) identified Sema4D as a major 
coupling factor expressed on osteoclasts that inhibits osteoblast differentiation. They found that mice 
with a global knockout of Sema4d had increased bone volume. (2) Terpos et al. (2) reported increased 
soluble Sema4D in serum and bone marrow plasma of patients with myeloma, a bone marrow cancer 
with uncoupled osteoclast activation and osteoblast suppression, compared to controls. (3) Sema4D 
and its primary receptor Plexin-B1 are commonly overexpressed in cancers. (4) Yang et al. (3) found 
that shRNA knockdown of Sema4D in MDA-MB-231 breast cancer cells decreased bone metastases 
in a standard xenograft model. (5) A humanized antibody that neutralizes Sema4D has shown 
antitumor activity in animal models and is under clinical testing in early phase clinical trials (4).
SeMA4D STRUCTURe AND ROLe iN HUMAN PHYSiOLOGY
Semaphorins form a highly conserved family of proteins that contain a signature amino-terminal 
sema domain. The semaphorin family contains more than 20 genes divided into seven classes, of 
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which classes III–VII are expressed in vertebrates. They have 
diverse roles in human biology including regulation of tumor 
growth and metastasis, angiogenesis, axonal guidance, bone 
formation, tissue regeneration, and autoimmunity (5).
Sema4D belongs to class IV of the Semaphorin family. In addi-
tion to the signature sema domain, the C-terminal region of 
Sema4D includes an IgG-like domain, a transmembrane domain, 
and a short cytoplasmic tail that contains one tyrosine phospho-
rylation site and multiple sites for serine–threonine phosphoryla-
tion. Membrane-bound Sema4D forms a stable homodimer via 
a disulfide bond between cysteines 679 within the sema domain. 
Proteolytic shedding of Sema4D by membrane-type 1-matrix 
metalloproteinase (MT1-MMP/MMP14) gives rise to soluble, 
dimeric Sema4D (sSema4D) (6). Both membrane-bound and 
soluble Sema4D can activate Plexin-B1 signaling.
Sema4D is expressed by many tissues including brain, kidney, 
and heart. However, Sema4D knockout mice have immune defects 
without other obvious organ dysfunctions, suggesting that its 
major role is in immune regulation. Sema4D is expressed strongly 
by resting T cells and weakly on B and antigen-presenting cells. 
Expression is increased upon cellular activation (7). Engagement 
of Sema4D enhances its association with the membrane protein 
tyrosine phosphatase CD45, which is expressed broadly in 
hematopoietic cells (8). The complex becomes active and recruits 
further proteins to sustain B and T cell activation and aggregation.
Most work on Sema4D function has focused on its role as a 
ligand in soluble form after proteolytic shedding. Several recep-
tors for Sema4D have been identified, including C-type lectin 
protein CD72, and three members of the plexin family; Plexin-B1, 
Plexin-B2, and Plexin-C1 (9–12). Target cells express different 
receptors, leading to a broad variety of potential responses to 
Sema4D in different tissues. CD72 is the main Sema4D receptor 
on immune cells, although monocytes and immature dendritic 
cells require Plexin-C1 and Plexin-B1, respectively. Plexins-B1 
and -B2 mediate the Sema4D responses on non-immune cells. 
CD72 (also known as Lyb-2) is a 45-kDa type II transmembrane 
protein of the C-type lectin family (13) which is expressed 
throughout B-cell differentiation (14). The CD72 cytoplas-
mic domain contains two immune-receptor tyrosine-based 
inhibition motifs that recruit the tyrosine phosphatase SHP-1, 
resulting in inhibition of src family kinases and JNK and B cell 
inhibition (15). Sema4D engagement of CD72 triggers tyrosine 
dephosphorylation of CD72, leading to SHP-1 dissociation 
(10), thereby relieving CD72-mediated B  cell inhibition. Since 
Sema4D and CD72 are expressed preferentially on T and B cell, 
respectively, their interaction couples T and B  cells to dial the 
immune reaction up or down. Dendritic cells, macrophages, and 
some subpopulations of T cells express CD72 (16). Sema4D may, 
therefore, play an additional role in T  cell communication via 
these other immune cells.
Plexins are transmembrane proteins with a sema ligand-
binding domain in their extracellular domain. Upon ligand 
binding, Plexin-B1 and Plexin-B2 extracellular domains undergo 
proteolysis by subtilisin-like proprotein convertases to further 
increase their affinity for Sema4D (17). The highly conserved 
cytoplasmic region of plexins is devoid of enzymatic activity, but 
it can interact, directly or indirectly, with small G proteins for 
various functions (18). Transduction cascades downstream of 
the Sema4D/Plexin-B1 complex vary, dependent on the different 
membrane proteins and G proteins recruited to the complex.
Figure 1 details downstream signaling of Sema4D/Plexin-B1. 
Without engagement with Sema4D, the cytoplasmic tail of 
Plexin-B1 is in an inactive conformation. R-Ras is in a GTP-bound 
state and activates membrane integrin to control cellular adhe-
sion to the extracellular matrix. Rac is not bound to Plexin-B1 
and promotes activation of p21-activated kinase (PAK) to activate 
LIMK1 and cofilin to increase actin polymerization and micro-
tubule assembly (19). Binding of Sema4D to Plexin-B1 alters 
Plexin-B1 conformation allowing recruitment of Rac1, which 
sequesters it from the PAK-LIMK1-cofilin signaling cascade, 
causing disassembly of actin fibers (20). Initiation of PlexinB1-
GAP activity inhibits R-Ras-mediated integrin activation, which 
blocks cell adhesion and increase cell motility and invasion (21). 
Deactivation of R-Ras further decreases the PI3K–Akt–GSK3β 
pathway, which leads to deactivation of CRMP-2 and subsequent 
microtubule disassembly (22).
Whether Sema4D/Plexin-B1 complexes activate or inhibit 
downstream GTPases also depends on their interactions with 
specific receptor tyrosine kinases: ErbB-2 or c-Met (23). In ErbB2 
expressing cells, binding of Sema4D to Plexin-B1 activates the 
intrinsic tyrosine kinase activity of ErbB-2, resulting in the phos-
phorylation of both Plexin-B1 and ErbB-2 (24), generating docking 
sites on Plexin-B1 for the SH2 domains of 1-phosphatidylinositol-
4,5-bisphosphate phosphodiesterase gamma-1/2 (PLCγ1/2) (25). 
The SH3 domain of the recruited PLCγ1/2 activates the guanine 
nucleotide-exchange factors (GEFs) LARG (leukemia-associated 
RhoGEF) and PRG (PDZ-RhoGEF) that constitutively bind 
to the PDZ binding site of the carboxyl-terminal sequence of 
Plexin-B1 (26). Activated RhoGEFs LARG and PRG mediate 
activation of the small GTPase RhoA, which cooperates with Ras 
to activate the serine/threonine kinases Raf and Rho-associated 
kinases (e.g., ROCK1/2) to stimulate various pathways, including 
mitogen-activated phosphokinases (MAPKs) ERK1/2 and p38, 
protein kinases (PI3/Akt—phosphatidylinositol 3′-kinase) (27). 
Downstream activation of MAPKs and PI3K control dendritic 
and axonal morphogenesis by differentially regulating branching 
and extension (27). On the other hand, Sema4D/Plexin-B1 can 
interact with Rnd1 to downregulate the GTPase activity of R-Ras, 
inducing growth cone collapse in hippocampal neurons (28). 
Plexin-B1 also binds and competes for activated Rho GTPase 
Rac, thus preventing Rac from activating its downstream effec-
tor PAK to initiate actin polymerization. In endothelial cells, 
Sema4D/Plexin-B1 signals stimulate PI3K-Akt to activate PYK2 
and Src to control endothelial cell migration (29). c-Met (HGF 
receptor tyrosine kinase) and macrophage stimulating protein 
(MSP, encoded by the Ron gene) are members of the Scatter 
Factor Receptors family. They share structural homology with 
Plexin-B1 (30, 31). In cells with c-Met expression but absent 
ErbB2, Sema4D/Plexin-B1 recruits and activates c-Met or Ron 
kinases to regulate cell motility and invasiveness. In normal fibro-
blasts, phosphorylation of c-Met creates a docking site for growth 
factor receptor bound-2 (Grb2), which then interacts with p190 
RhoGAP and inactivates RhoA, causing inhibition of fibroblast 
motility (32).
FiGURe 1 | Schematics of Sema4D/Plexin-B1 signaling. (A) In the absence of Sema4D, the cytoplasmic tail of Plexin-B1 is in an inactive conformation. R-Ras is  
in a GTP-bound state to collaborate with integrin and control cellular adhesion to the extracellular matrix (ECM). With Plexin-B1 in an inactive state, Rac activates 
p21-activated kinase (PAK) to trigger LIMK1 signaling and downstream phosphorylation of cofilin, which results in increased actin polymerization and microtubule 
assembly. (B) Sema4D binding to Plexin-B1 alters the Plexin-B1 conformation, recruits Rac1 to the complex, and inhibits activation of the PAK–LIMK1–cofilin 
signaling cascade. In addition, R-Ras recruitment to the Sema4D/Plexin-B1 complex inhibits its ability to regulate integrin-mediated activation, resulting in increased 
cell motility. Deactivation of R-Ras further decreases PI3K-Akt GSK3β pathway, which leads to deactivation of CRMP-2 and subsequent microtubule disassembly.  
In an ErbB2-dependent signaling step, PLCγ1/2 is recruited to Plexin-B1 via its SH2 domain. Structural interaction of the PLCγ1/2 SH3 domain triggers PDZ-
RhoGEF/LARG complex, resulting in RhoA activation. Active GTP-RhoA acts on Raf and Rho-associated kinases (ROCK1/2), which in turn stimulate PYK2 to 
induce cell invasiveness and migration. (C) Sema4D-Plexin-B1 signaling inhibits osteoblast differentiation. Plexin-B1/ErbB2-dependent RhoA activation stimulates 
activation of downstream kinase ROCK, which phosphorylates the insulin receptor substrate 1 (IRS1). This causes suppression of insulin like growth factor 
(IGF1)-dependent signaling and blocks osteoblast differentiation.
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SeMA4D iN BONe PHYSiOLOGY
Successful crystallization of Sema4D and solution of its structure 
led to a recognition of the homology between the Sema4D 
homodimer and the αVβ3 integrin heterodimer, the first clue 
to a role for Sema4D in bone biology (33). αVβ3 integrin is an 
osteoclast regulator, and β3 integrin knockout mice become 
progressively osteosclerotic with age due to dysfunctional osteo-
clasts that fail to polarize correctly and display abnormal ruffled 
membranes (34).
Two groups reported an increased bone mass in Sema4D 
knockout animals and the expression of Sema4D in osteoclasts 
but not osteoblasts (1, 35). Negishi-Koga and coworkers com-
prehensively surveyed osteoclasts and osteoblasts for expression 
of candidate molecules to couple bone formation to resorption, 
including the members of the ephrin, netrin, semaphorin, and slit 
gene families. They found that only Sema4D was highly expressed 
in RANKL-activated osteoclasts. Utilizing a soluble Fc receptor-
Sema4D fusion protein, they evaluated directly the effects of 
the Sema4D extracellular domain on osteoblasts. Fc-Sema4D 
inhibited the osteoblast differentiation markers alkaline phos-
phatase and osteocalcin, as well as the formation of mineralized 
nodules in culture, without a change in osteoblast proliferation. 
Co-immunoprecipitation confirmed a complex of Fc-Sema4D 
with Plexin-B1, which is highly expressed in osteoblasts. This 
complex leads to ErbB2 phosphorylation and downstream activa-
tion of RhoA. Plexin−/− animals, as well as mice expressing an 
osteoblast-targeted dominant negative RhoA, had a high bone 
mass due to enhanced osteoblastic bone formation, recapitulating 
the bone phenotype of the Sema4d−/− mice. A recent study used 
optoPlexin (optogenetic activation of Plexin-B1) in osteoblasts to 
show that Plexin-B1 activation results in retraction of the leading 
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edge and induces distal membrane protrusions, causing the osteo-
blasts to migrate. Thus, osteoclast-produced Sema4D may cause 
repulsion of osteoblasts via activation of both the RhoA and ras-
GTP pathways (36). Overall, these findings support the function 
of the Sema4D/Plexin-B1/RhoA axis in osteoblast inhibition by 
osteoclasts (1). However, Sema4D’s regulation of bone mass may 
be more complicated. Dacquin et al (35) noted that the increased 
bone mass phenotype in Sema4d−/− mice primarily occurred 
in mature female mice. The increased bone mass phenotype in 
Sema4d−/− mice was not reversed after a transplantation of bone 
marrow cells from wild-type mice, as a source of new osteoclasts. 
Sema4d−/− mice have impaired ovarian function, small litter size, 
and decreased hypothalamic gonadotropin-hormone releasing 
hormone. The authors propose an indirect mechanism by which 
Sema4D regulates bone mass via the hypothalamic–pituitary–
ovarian axis (35).
Serum Sema4D has been explored as a biomarker in osteo-
porosis, with conflicting results to date, likely reflecting different 
patient populations, the non-randomized nature of the trials and 
different time points for Sema4D analysis. In postmenopausal 
women, serum Sema4D was higher among those with osteo-
porosis (37). However, in an open label study of osteoporotic 
women receiving the osteoclast-targeting agents zoledronic 
acid or RANKL monoclonal antibody denosumab or the bone-
anabolic agent teriparatide (PTH1-34), serum Sema4D decreased 
after 3 months of teriparatide treatment, while it increased with 
denosumab and zoledronic acid (38). There was no attempt to 
correlate the Sema4D levels with degree of osteoporosis, and 
serum Sema4D was assayed at only one time point, not allowing 
a determination of kinetics, which may differ among treatment 
groups.
Congenital defects due to mutation or loss of Sema4D have 
been little studied in humans. Segmental copy number loss in the 
region of the Sema4D gene was seen in one third of patients with 
acetabular dysplasia, which increases risk of osteoarthritis, but a 
causal relationship was not explored (39).
Sema4D has been implicated in bone and joint inflammation. 
In rheumatoid arthritis (RA), Sema4D was elevated in both serum 
and synovial fluid from RA patients, and disease activity markers 
were correlated with serum Sema4D levels. Sema4D-expressing 
cells also accumulated in RA synovium, and sSema4D-induced 
tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) 
production from CD14+ monocytes (40). Movila and group 
explored treatment-related osteonecrosis of the jaw and showed 
increased Sema4D-expressing γδ-T cells in bone lesions, which 
were decreased by anti-Sema4D antibody (41). In osteoarthritis, 
bone tissue had low Plexin-B1 expression compared to age- and 
gender-matched cadaveric control bones, indicating that the loss 
of Sema4D/Plexin-B1 inhibition of osteoblast activity may lead 
to an increased bone volume fraction and decreased bone matrix 
mineralization, contributing to osteoarthritis (42).
Elevated Sema4D is observed in diseases unrelated to the 
musculoskeletal systems, including hemorrhagic fever with renal 
syndrome (43) and autoimmune diseases (44). Inflammation and 
increased shedding from peripheral blood mononuclear cells 
are possible sources. Serum Sema4D is also increased in non-
inflammatory condition such as atrial fibrillation (45). The value 
of sSema4D as a biomarker in some of these diseases may warrant 
further investigation.
SeMA4D iN CANCeR
While other semaphorins such as Sema3B and 3F are tumor sup-
pressors, Sema4D promotes tumor growth (46, 47). Sema4D and 
Plexin-B1 are abnormally expressed in various cancers and have 
been associated with invasive phenotypes and poor prognosis. 
The mechanisms by which Sema4D confers these features are 
complex and involve both tumor cells and their microenviron-
ment. While not directly linked to malignant transformation, 
Sema4D/Plexin-B1 signaling contributes to many critical aspects 
of cancer progression, including proliferation, invasion, angio-
genesis, immune escape, and metastasis. We summarize the role 
of Sema4D/Plexin-B1 in cancers based on overexpression of 
Sema4D or Plexin-B1 by the cancer cells or by other cells in the 
tumor microenvironment including immune cells, and the role of 
Sema4D/Plexin-B1 in distant metastasis.
Because of its known role in lymphoid cells, Sema4D expres-
sion in cancer was first evaluated in lymphoma and lymphoblastic 
leukemia. T cell lymphomas universally express Sema4D, while 
only a minority of B cell lymphomas are Sema4D positive (48), 
paralleling the expression of Sema4D by normal T and B cells. 
In chronic lymphocytic leukemia (CLL), CD38 is a known negative 
predictor of survival. CD38 binds to (49) stromal cells expressing 
CD31, leading to relocalization of Sema4D, facilitating its binding 
to Plexin-B1 on bone marrow cells. The increased expression of 
Plexin-B1 in stromal cells, follicular dendritic cells, and activated 
T-cells, enhances the complex interplay of CD38/CD31 and 
Sema4D/Plexin-B1 to sustain CLL growth (50, 51).
Sema4D is highly expressed by many solid tumors includ-
ing prostate, glioma, lung, ovarian, sarcoma, and cutaneous 
squamous cell carcinoma. Expression is correlated with tumor 
aggressiveness and poor prognosis, but controversial data exist 
for some tumors. In an array of 888 genes, Sema4D mRNA was 
highest in early stage breast cancer compared to normal tissue 
and downregulated in advanced disease (52). Jiang and coworkers 
confirmed high Sema4D protein in breast cancer cell lines com-
pared to normal breast epithelial cells. In addition, knockdown of 
Sema4D by shRNA inhibit breast cancer proliferation and tumor 
growth in xenografts (49). Malik et  al., however, showed an 
opposite result of decreased Sema4D, Plexin-B1 and -B2 protein 
in primary breast tumors of patients who subsequently devel-
oped local recurrence, compared to the patients who remained 
disease-free (53). These studies used whole tumor tissues and 
may be confounded by different cell types within the tissue, since 
other cells in the microenvironment, including endothelial cells 
and macrophages, also express Sema4D. In whole-blood RNA, 
Sema4D was identified as one of six RNAs strongly predicting 
shorter survival among patients with castrate-resistant prostate 
cancer (54). Most data on Sema4D and clinical outcomes are 
based on small sample sizes with subjects receiving different 
treatments and not controlled for other prognostic markers. 
Prognostic value of Sema4D requires further validation in larger 
cohorts of patients, controlled for treatment types and other 
variables.
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Overexpression of Plexin-B1 has been reported in skin, prostate 
and pancreatic cancers, and sarcoma (55–57). It correlates with 
lymph node metastasis, distant metastasis, and poor prognosis in 
patients with pancreas cancer (56). Plexin-B1 activation increases 
phosphorylation and translocation into the nucleus of the andro-
gen receptor (AR), leading to activation of AR-regulated genes, 
which could play a role in castration resistance in prostate cancer 
(58). However, Rody et al. showed a rather opposite finding in 
breast cancer, in which loss of Plexin-B1 identifies a subgroup of 
estrogen receptor expressing breast cancer with high proliferative 
rate and hormone resistance (59). Cancer cell lines that express 
higher levels of Plexin-B1 exhibit increased perineural invasion. 
The mechanism is proposed to be the attraction of the cells due to 
Sema4D production from the nerves. Interestingly, higher nerve 
density in tumors expressing Sema4D (60) suggests that these 
tumors may use nerve-secreted factors for growth, pointing to a 
possible role of Sema4D in cancer pain.
While no Sema4D mutation has been reported in human can-
cers, Plexin-B1 mutations and copy number changes are noted 
commonly in various cancers, including melanomas, pancreas, 
breast, and prostate cancers (58, 61, 62). Thirteen somatic mis-
sense mutations in the cytoplasmic domain of Plexin-B1 were 
found in 46% of prostate cancers. Mutational hotspots mapped to 
the Rho GTPase binding domain in the cytoplasmic region of the 
receptor, causing loss of Rac and R-Ras binding and R-RasGAP 
activity. This resulted in an increase in cell motility, invasion, 
and adhesion, and could explain the metastatic phenotype (61). 
In some cancers, however, Plexin-B1 acts as a tumor suppressor. 
For example, Plexin-B1 is lost in deep and metastatic melanomas. 
Introducing Plexin-B1 into melanoma cells suppresses c-Met 
and hence proliferative responses to HGF. Increased Plexin-B1 
confers resistance to cisplatin (63). A similar finding was noted 
in clear cell carcinoma (64). Sema4D/Plexin-B1 responses may 
vary among different cell lines of the same tumor type. Sema4D/
Plexin-B1 increased the proliferative and invasive potential of 
LNCaP prostate cancer cells through the activation of ErbB2 and 
Akt, but decreased the motility and proliferation of PC3 prostate 
cells (65).
Different phenotypes of Sema4D/Plexin-B1-expressing tumors 
may depend on the expression of its partner proteins ErbB2 and 
c-Met. Since c-Met is one of the most commonly deregulated onco-
gene in cancers, its collaboration with Sema4D/Plexin-B1 is an 
alternative pathway to promote tumor invasion (66). Constitutive 
activation of Met in tumor cells with high Plexin-B1 can occur in 
the absence of Sema4D (66). T lymphoma invasion and metastasis 
1 (Tiam1) is another Rac-specific guanine nucleotide-exchange 
factor that is activated by Sema4D/Plexin-B1 to stimulate Rac and 
promote proliferation, invasion, and metastasis in oral squamous 
cell carcinoma (67). In cancer cells that express both Sema4D 
and Plexin-B1, the pair could function in an autocrine/paracrine 
manner, although this requires future study.
In addition to direct proliferative actions in cancer cells, 
Sema4D/Plexin-B1 abnormalities within the tumor niche sup-
port cancer progression by promoting angiogenesis. Sema4D/
Plexin-B1 function in angiogenesis was first described by Basile 
and coworkers (68), who showed that recombinant Sema4D-
induced chemotaxis of endothelial cells, in  vitro tubulogenesis 
and enhanced blood vessel formation in an in vivo mouse model. 
Sema4D/Plexin-B1 phosphorylation of c-Met promotes angio-
genesis in a non-redundant manner from HGF (69). Sema4D 
can also stimulate angiogenesis via a c-Met-independent pathway 
through recruitment of PDZ-RhoGEF and LARG to the Sema4D/
Plexin-B1 complex leading to Rho pathway activation, followed 
by downstream AKT and NF-κB activation and increased expres-
sion of proangiogenic IL-8 (70). Hypoxia induces Sema4D in a 
HIF-1-dependent manner. Sema4D then cooperates with VEGF 
to promote tumor growth and vascularity (71, 72). In addition, 
tumor-secreted Sema4D increases endothelial expression of 
platelet-derived growth factor-B and angiopoietin-like protein 
4, which promote endothelial proliferation and vascular perme-
ability (73). Lentiviral overexpression of Sema4D in colorectal 
cancer cell lines caused a proangiogenic response regardless of 
VEGF status (74). Sema4D may also be a biomarker for tumor 
angiogenesis, since its expression in ovarian cancer correlates 
with HIF-1, VEGF, and poor prognosis. Sema4D inhibition 
causes dissociation of endothelial cells from pericytes, a crucial 
step for successful antiangiogenic therapy (75). Both VEGF and 
Sema4D may cooperate in a multi-step process to reorganize the 
vasculature within the malignant niche. Tumor cells increase their 
Sema4D expression as an escape mechanism from anti-VEGF 
treatment (75). Concurrent targeting of VEGF and Sema4D 
may have additive or synergistic antiangiogenic effects. Sema4D 
may also support lymphangiogenesis, since Sema4D targeting 
with neutralizing antibody or shRNA suppressed VEGF-C and 
VEGF-D, key factors for lymphangiogenesis (76).
The role of Sema4D in immune regulation supports the impor-
tance of dysregulated Sema4D in immune escape of cancer cells. 
In a head and neck cancer model, tumor-secreted Sema4D pro-
moted the expansion of myeloid-derived suppressor cells, which 
inhibit T-cell functions (77). Sema4D affects both the activities 
of immune cells and their recruitment to the tumor microenvi-
ronment. Delaire and coworkers noted that Sema4D inhibited 
both spontaneous and chemokine-induced migration of human 
monocytes (78). Strong expression of Sema4D at the invasive 
margins of actively growing tumors changed the infiltration and 
distribution of leukocytes within the tumor microenvironment. 
Neutralization of Sema4D by blocking antibodies disrupted this 
gradient of expression and enhanced recruitment of activated 
monocytes and lymphocytes into the tumor. This shifted the bal-
ance of cells and cytokines in a pro-inflammatory and antitumo-
rigenic direction and was associated with durable tumor rejection 
in murine Colon26 and ERBB2 + mammary carcinoma models 
(4). These functions are at odds with the known roles of Sema4D 
in T and B cell activation. The dual nature of Sema4D between 
pro and antitumor action may depend on subsets of immune cells 
in the tumor niche, which in turn may depend on the plasticity 
of macrophages and T cells within the tumor. Classical activation 
of macrophages with interferon γ (M1) promotes the differentia-
tion of cytotoxic T cells, which can improve antigen phagocytosis. 
However, alternative pathway of macrophage activation by IL-4, 
IL-14, or LPS gives rise to M2 macrophages. Tumor-associated 
monocytes are M2 and communicate effectively with regulatory 
T  cells (Treg) to suppress antigen recognition and promote an 
inflammatory tumor microenvironment, angiogenesis, and 
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tumor progression (79). In tumors with high M2 macrophages 
and Tregs, Sema4D may contribute to immune suppression, even 
though in normal physiology, Sema4D is required for T and B cell 
function.
Sema4D may promote metastasis at distant sites. Many cancer 
cells, including head and neck squamous cell carcinoma lines, 
express the membrane-tethered collagenase, MT1-MMP which 
cleaves Sema4D. sSema4D could thus promote angiogenesis and 
cell migration both locally and at distant sites, thereby promoting 
metastasis (80).
SeMA4D iN THe BONe MARROw 
MeTASTATiC NiCHe
The involvement of Sema4D in bone biology and cancer progres-
sion suggests a role in bone metastasis. Bone is the most com-
mon site of distant metastases for prostate and breast cancers. 
Bone metastases are driven by complex interactions between 
cancer cells, bone marrow cells, and bone cells, often leading to 
increased osteoclast and suppressed osteoblast activities. Even 
in osteosclerotic metastasis, occurring in prostate and some 
breast cancers, the newly formed bone is poorly organized, and 
osteoclasts remain activated, leading to loss of bone quality. 
Osteolysis with osteoblast suppression is a hallmark of multiple 
myeloma, an incurable blood cancer that originates within bone 
(81, 82). Current treatments are limited to osteoclast-targeting 
agents, which provide palliative benefit with marginal effect 
on tumor control. Zoledronic acid modestly prevents bone 
metastases in breast and prostate cancer xenograft models, 
but its benefit as a bone metastasis prevention is limited to 
postmenopausal women (83). No survival advantage was seen 
in premenopausal women or men with prostate cancers. This 
evidence suggests that osteoclast targeting alone is inadequate 
for tumor control.
Sema4D is a coupling molecule of osteoclasts and osteoblasts 
(1). In the tumor niche, Sema4D from the tumor cells and 
activated osteoclasts inhibits osteoblast differentiation, while 
inducing IL-8 secretion to further promote osteoclast prolifera-
tion and activity (70). Because soluble Sema4D can reach distant 
bone sites, it could hypothetically prime the bone niche to 
support future metastasis. Since tumor cells with high Sema4D 
also have high motility and invasiveness and Sema4D promotes 
angiogenesis, Sema4D could contribute to metastasis at both 
at the primary tumor site and distant sites. This notion is sup-
ported by a decrease in skeletal metastasis when Sema4D was 
knocked down using shRNA in the MDA-MB-231 breast cancer 
model (3).
Terpos and coworkers (2) showed increased Sema4D in peri-
pheral blood and bone marrow plasma from myeloma patients 
compared to controls. We have shown that myeloma cell lines 
and primary myeloma cells express Sema4D at higher levels 
than MDA-MB-131 cells. In addition, we found that coculture of 
myeloma cells with bone increased expression of Sema4D by both 
tumor cells and bone (84). Myeloma cells, as well as breast cancers, 
express MMP14 (MT1-MMP), which releases membrane-bound 
Sema4D by proteolytic cleavage (85). Sema4D can promote angi-
ogenesis, which is required for myeloma progression. Sema4D is, 
therefore, a potential target in myeloma, as well as in cancers that 
metastasize to the skeleton.
STRATeGY FOR SeMA4D/PLeXiN-B1 
TARGeTiNG
VX15/2503 is the first and only currently available humanized 
Sema4D blocking antibody in clinical testing. The antibody was 
generated in Sema4D−/− mice by using a panel of SEMA4D-
specific hybridomas that react with murine, primate, and human 
SEMA4D (86). VX15/2503 bound with high affinity (1–5 nmol/L) 
to Sema4D and achieved complete Sema4D blockade in animal 
models, and its activity was subsequently confirmed in humans. 
No dose-limiting toxicity or maximal tolerated dose was observed 
at the dose required for complete Sema4D blockade in phase I 
clinical trials of multiple sclerosis and refractory solid malignan-
cies (87, 88).
In the phase I study of 42 patients with refractory cancers 
receiving dose escalation of VX15/2503, one patient (2.4%) 
achieved partial response and 27 patients (64.3%) achieved 
long duration stable disease. Subjects with elevated baseline B 
and T  lymphocytes exhibited longer progression-free survival, 
suggesting involvement of immune-mediated antitumor activity. 
Bone parameters and development of metastases were not end-
points. Tumor response was based on reduction in tumor size; 
therefore, patients with isolated bone metastases without other 
measurable tumor masses were not included.
The large, planar binding interface of the Sema4D/Plexin-B1 
interaction makes it challenging to target with small molecules. 
Matsunaga and coworkers discovered a macrocyclic peptide, 
PB1m6, which binds Plexin-B1 with high affinity and specifically 
inhibits binding of the physiological ligand Sema4D and com-
pletely suppressed Sema4D-induced cell collapse in  vitro (89). 
No data for this peptide in vivo or in cancer models are currently 
available.
Because of the central role of Sema4D in osteoblast inhibi-
tion, Zhang and group developed bone-specific drug delivery 
of Sema4D siRNA using N-(2-hydroxypropyl) methacrylamide 
copolymers with d-aspartic acid octapeptide (90). They showed 
that in an osteoporotic animal model induced by ovariectomy, 
weekly intravenous injections of this compound decreased osteo-
clast Sema4D expression and increased osteoblast differentiation. 
Treated animals showed higher femoral bone volume both in 
prevention and treatment models. Similar reduction of bone loss 
was seen in alveolar bone of the mandibles (91). Clinical testing 
of this molecule in patients has not been reported, but the study 
provides a proof of benefit for Sema4D targeting in bone.
While blocking the Sema4D/Plexin-B1 complex is of potential 
benefit in cancers and neuroinflammatory diseases, some cancers 
are growth inhibited by Sema4D signaling. In an acute myeloid 
leukemia cell line Kasumi-1, Sema4D binding of CD72, its pre-
ferred receptor in immune cells, leads to inhibition of growth and 
cell death, as a result of phosphorylation of CD72, the formation 
of the CD72–SHP-1 complex and dephosphorylation of src fam-
ily kinases and JNK (15). Future development of Sema4D target-
ing should take into account the cellular context where Sema4D 
exerts its function.
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DiSCUSSiON
We highlight Sema4D as a novel regulator of bone homeostasis. 
Sema4D also supports crucial steps in tumor progression, ranging 
from invasion, migration, angiogenesis, and immune suppres-
sion, to the pathological alteration of the tumor niche to support 
metastasis. Targeting Sema4D in the clinic has become practical 
with the development of a specific neutralizing antibody, which 
has low toxicity and an impressive response rate in early clinical 
trials of patients with refractory cancers. Because of the potential 
role of Sema4D in bone metastasis, this molecule should be 
further explored in these specific disease groups, and bone metas-
tases should be included in clinical endpoints. Our preliminary 
data also support the potential of Sema4D blockade in multiple 
myeloma. Baseline B and T  cell profiles have been correlated 
to response in a preliminary cancer clinical trial and should be 
further developed as a screening tool to identify patients likely 
to respond, or as a biomarker of response. In addition, Sema4D 
targeting may have synergistic antitumor effects when combined 
with immunomodulatory agents, warranting further study.
A major open question is whether Sema4D from non-
osteoclast sources plays a significant role to inhibit osteoblast 
activity in cancer/bone diseases. Sema4D is expressed on tumor 
cells that colonize bone, while cells of the microenvironment 
other than osteoclasts may also express Sema4D. Although the 
extracellular domain can be proteolytically shed, it seems unlikely 
that local sSema4D concentrations are sufficient to activate 
osteoblast Plexin-B1. Both Negishi-Koga et al. (1) and Yang et al. 
(3) showed osteoblast suppression with micrograms per milliliter 
amounts of sSema4D:Fc fusions, orders of magnitude higher than 
those found in bone marrow plasma from multiple myeloma by 
Terpos et al. (2). Non-osteoblast and tumor sources of Sema4D 
could still inhibit osteoblast activity by direct cell:cell contact. 
Direct evidence for such actions is lacking; they may occur only 
in the context of co-receptors specific to the osteoclast. Patient 
data from clinical trials with Sema4D-neutralizing antibody 
could provide answers to these questions. Patients receiving 
antibody treatment should have increased bone mineral density. 
If the osteoclast Sema4D axis is the only significant contributor 
to osteoblast suppression, then there may be little bone effect of 
treatment in patients also receiving anti-osteoclast drugs (bis-
phosphonates or denosumab), which are the standard of care for 
cancer bone diseases.
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